Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
A take-home ECG patch given to fainting patients in the ER more than doubled the detection of dangerous heart rhythm problems and cut deaths in half, according to the ASPIRED trial. While it didn't reduce how often patients fainted, it dramatically improved diagnosis and led to faster, targeted treatment. Results were published in the New England Journal of Medicine.
For the roughly half of patients who leave the ER after a fainting episode with no clear diagnosis, a small wearable heart monitor may be a game-changer. The ASPIRED trial, presented at the European Society of Cardiology Congress and published in the New England Journal of Medicine, tested whether fitting patients with a 14-day adhesive ECG patch (the BodyGuardian Mini) right at their emergency department visit could improve outcomes compared to standard care.
The trial enrolled 2,234 patients across 45 U.K. hospitals. While the primary endpoint — reducing how often patients fainted over the following year — wasn't met, the secondary findings were striking. Extended monitoring more than doubled the detection of clinically significant cardiac arrhythmias and was associated with a 50% reduction in all-cause mortality.
By the Numbers
Why it matters: Unexplained syncope is a common and potentially dangerous ER presentation. Catching a hidden arrhythmia early — and treating it promptly with pacing or antiarrhythmic drugs — could be the difference between life and death for these patients.
